This site is intended for healthcare professionals

FDA accepts and grants priority review for BLA of lecanemab for early Alzheimer’s disease under the accelerated approval pathway.

Read time: 1 mins
Published:7th Jul 2022

Eisai Co., Ltd. and Biogen Inc. announced that the FDA has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab (development code: BAN 2401), an investigational anti-amyloid beta (A) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain.

Eisai’s application, which was completed in early May 2022 has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of January 6, 2023.

Condition: Alzheimers
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.